| Revenue growth | FY26 revenue ₹66.9cr; H2 revenue up 23% YoY to ₹41.63cr. |
|---|---|
| Margins | Gross margins improved 54% to 59%; H2 EBITDA margin at 26.3%. |
| Demand visibility | Strong recurring revenue at 93% of business; doctor base grew to 6300+. |
| Management confidence | High; aiming for 30% CAGR and Main Board listing within 3 years. |
Growth
FY26 revenue grew 8.6% YoY to ₹66.9cr; PAT increased to ₹6.6cr from ₹6cr. H2 revenue surged 64.4% sequentially.
Outlook
Targeting 30% CAGR and main board listing in 3 years. Launching Xelix clinic platform to reach 50 clinics.
Risks
Business seasonality (H1/H2 split), regulatory delays in product licensing, and high working capital requirements for inventory maintenance.
Earnings Call filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹70.00
- Market cap
- ₹99.21 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 14.9×Sector 57.8×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies Earnings Call: Key Takeaways
Aakaar Medical Technologies reported FY26 revenue of INR 67 Cr (up 8.6%) and PAT of INR 6.63 Cr (up 10%). The company is shifting towards an asset-light DODO clinic model via its Xelix platform.
Aakaar Medical Technologies H2 FY26 Results: Net Profit ₹7.4 Cr, Up 32.1% YoY
Aakaar Medical Technologies Ltd reported revenue from operations of ₹41.6 Cr (+22.7% YoY) and net profit of ₹7.4 Cr (+32.1% YoY) for H2 FY26.
- Key figure
- Net profit ₹7.4 Cr · +32.1% YoY
Aakaar Medical Technologies Earnings Call: Key Takeaways
Aakaar Medical Technologies reported H2FY26 revenue of ₹41.6 Cr and PAT of ₹7.4 Cr, successfully pivoting to higher-margin owned brands and cash-first billing.